European Journal of Clinical Pharmacology

, Volume 32, Issue 3, pp 325–325 | Cite as

Drug hydroxylator phenotype in Hungary

  • I. Szórády
  • A. Sánta
Letters To The Editors

Key words

debrisoquine hydroxylator phenotype pharmacogenetics side-effect paediatric pharmacology drug metabolism 


  1. 1.
    Idle JR, Smith RL (1979) Polymorphism of oxidation at carbon centers of drugs and their clinical sigificance. Drug Metab Rev 9: 301–317Google Scholar
  2. 2.
    Kalow W (1982) Ethnic differences in drug metabolism. Clin Pharmacokinet 7: 373–400Google Scholar
  3. 3.
    Kalow W (1985) Pharmacoanthropology. Ann Biol Clin 43: 519–534Google Scholar
  4. 4.
    Lennard MS, Silas JH, Smith AJ, Tucker GT (1977) Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr 133: 161–166Google Scholar
  5. 5.
    Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102–105Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • I. Szórády
    • 1
  • A. Sánta
    • 1
  1. 1.Children's HospitalSzegedHungary

Personalised recommendations